淋巴瘤临床研究—2022年ASCO会议报告

Clinical studies on lymphoma—the review of 2022 American Society of Clinical Oncology annual meeting

淋巴瘤是一组起源于淋巴造血系统具有高度异质性的恶性肿瘤,主要分为霍奇金淋巴瘤(Hodgkin’s lymphoma,HL)和非霍奇金淋巴瘤(non-Hodgkin’s lymphoma,NHL)。淋巴瘤的治疗以全身治疗为主,传统方案对患者的疗效及生存达到了瓶颈。近年来,治疗淋巴瘤的新药及新方案不断涌现,免疫治疗、细胞治疗及靶向治疗进展迅速,其中双特异性抗体、抗体偶联药物(antibody-drug conjugate,ADC)和嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)的出现为淋巴瘤患者提供了更多选择。本文将对2022年美国临床肿瘤学会(ASCO)年会议中淋巴瘤领域的临床研究报告进行综述。

Lymphoma is a group comprising highly heterogeneous malignancies originating from the lymphatic hematopoietic system and mainly classified into Hodgkin's lymphoma(HL)and non-Hodgkin's lymphoma(NHL).Lymphoma treatment is mainly systemic,and traditional regimens have reached a bottleneck regarding efficacy and survival of patients with lymphoma.Recently,new drugs and regimens for lymphoma treatment have emerged.Rapid development was observed in immunotherapy,cell therapy,and targeted therapy.With the application of bispecific antibody,antibody-drug conjugate(ADC),and chimeric antigen receptor T-cell(CAR-T),more options were available for patients with lymphoma.The article provides an overview of the recent clinical studies on lymphoma presented at 2022 American Society of Clinical Oncology annual meeting.